- BrightInsight announced it raised $25 million in Series A funding co-led by New Leaf Venture Partners and Eclipse Ventures, which will be used to enhance its platform
BrightInsight has announced it raised $25 million in Series A funding co-led by New Leaf Venture Partners and Eclipse Ventures. This round of funding will enable BrightInsight to further enhance the functionality of its BrightInsight Platform and accelerate global commercialization efforts for the leading global regulated digital health platform serving biopharma and medtech customers. And BrightInsight will also further integrate its platform into the broader healthcare ecosystem, including Electronic Health Records (EHRs), payers, and disease management programs.
“Since the launch in 2018, our BrightInsight Platform has become the leading global regulated digital health platform for the world’s top biopharma and medtech companies,” said BrightInsight CEO and co-founder Kal Patel, M.D., MBA. “Our investors have strong pedigrees in healthcare as well as software and technology, which clearly validates our success thus far. This financing enables us to continue to invest in our differentiated platform while also integrating our solutions into the broader healthcare ecosystem globally.”
The BrightInsight Platform is a medical-grade Internet of Things (IoT) platform built under a robust ISO 13485:2016 certified Quality Management System for supporting and optimizing regulated drugs, devices, and software through integrated data and actionable insights. And the platform also enables customers to increase patient adherence and engagement.
“It’s clear that digital technologies are critical to transforming the healthcare system,” added New Leaf Venture Partners managing director Vijay Lathi. “We believe that BrightInsight will be a central piece in that transformation by enabling biopharma and medtech companies to deploy clinically impactful digital health solutions that have the potential to improve the quality of patient care while also reducing costs.”
Due to its privacy, security, regulatory, and quality certifications, BrightInsight was selected as Novo Nordisk’s digital health partner to develop innovative solutions for diabetes patients. And BrightInsight also announced the launch of a dosing calculator to treat patients with Hemophilia A — which was sponsored by F. Hoffmann-La Roche.
“Bringing healthcare to the edge will revolutionize patient care. While personalized medicine has long promised to deliver life-changing results, there has been limited adoption due to the lack of a secure, regulated infrastructure,” explained Justin Butler of Eclipse Ventures. “The medical-grade BrightInsight Platform will accelerate a new class of regulated therapies — from Software as a Medical Device to connected drugs and devices — delivering improved patient outcomes and experiences.”
The BrightInsight Platform is HITRUST CSF Certified and HITRUST Certified of the NIST Cybersecurity Framework for managing risk, improving security posture, and meeting compliance requirements. And the BrightInsight Platform is also ISO/IEC 27001:2013 certified, HIPAA and GDPR compliant and certified under both the EU-U.S. and Swiss-U.S. Privacy Shield frameworks.
“As connected medical devices and therapeutics continue to proliferate, the BrightInsight Platform serves as the ideal regulated cloud solution to securely manage the new data these products generate,” commented John Carlson of Flex Medical Solutions. “As a strategic partner, Flex will continue to support the BrightInsight Platform and work closely with the team to deliver reliable and innovative Sketch-to-Scale® health solutions for our biopharma and medtech customers around the world.”